US Lawmakers Want Answers From FDA On Infant Formula Shortage Following Abbott Recall
House Appropriations and Energy and Commerce subcommittees will ask about Abbott Nutrition’s recall of infant formula made at its Sturgis, MI, facility. “We are doing everything in our power to ensure there is adequate product available where and when they need it,” says FDA Commissioner Robert Califf.
You may also be interested in...
Reckitt Seeing Softening VMS Demand As OTC Remains Resilient
While sales remain strong for its cold and flu brands as the winter illness season gets underway, Reckitt is seeing demand soften for its dietary supplements as consumers rein in spending on more discretionary categories. This has not, however, had a major impact on Reckitt's Health business, which posted sales up 19% in Q3.
USDA Examines Potential Production Regulation Changes To Prevent Powder Formula Contamination
USDA Food Safety and Inspection Service’s National Advisory Committee on Microbiological Criteria for Foods schedules hearing for 15 November to consider a report from FDA on presence of Cronobacter species bacteria in powder formula products.
Abbott Concludes Former Employees’ Allegations Concerning Michigan Formula Plant ‘Unfounded’
Abbott’s Q3 worldwide sales of formula and other pediatric nutritionals were down 24.8% on reported basis. It plans spending $500m on a new formula facility after finding the US “would benefit from more manufacturing capacity and redundancy.”